This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tanvetyanon, T. Articles by Bepler, G. Search for Related Content PubMed PubMed Citation Articles by Tanvetyanon, T. Articles by Bepler, G. Related Articles Related Editorial Related Correspondence Social Bookmarking                            What's this?

Computed Tomography Response, But Not Positron Emission Tomography Scan Response, Predicts Survival After Neoadjuvant Chemotherapy for Resectable Non–Small-Cell Lung Cancer

Tawee Tanvetyanon, Edward A. Eikman, Eric Sommers, Lary Robinson, David Boulware, Gerold Bepler

From the Division of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Corresponding author: Tawee Tanvetyanon, MD, 12902 Magnolia Dr, Tampa, FL 33612; e-mail: tanvett{at}moffitt.org

Purpose Tumor response is considered a surrogate marker of survival. We investigated whether tumor response based on computed tomography (CT) scan or whole-body [¹⁸F]fluorodeoxyglucose positron emission tomography (PET) scan after neoadjuvant chemotherapy for resectable non–small-cell lung cancer (NSCLC) is prognostic of survival.

Patients and Methods Two consecutive phase II clinical trials were jointly analyzed. Patients underwent CT and PET scans before and after completion of neoadjuvant chemotherapy, followed by surgery.

Results Eighty-nine patients were included. Patients with a partial or complete response based on Response Evaluation Criteria in Solid Tumors categories (n = 33) had a better overall survival than those with stable or progressive disease (n = 56; median survival time, not reached v 36 months, respectively; P = .04). Of all patients, those with response in the highest quartile had 1- and 2-year survival rates of 100% and 81%, respectively, compared with 77% and 61%, respectively, among patients in the lowest quartile. However, on the basis of visual analysis of PET scan, patients with a metabolic response (n = 28) had no significant difference in survival compared with patients without response (n = 61; median survival time, 35.6 months v not reached, respectively; P = .94). In addition, on the basis of a semiquantitative analysis of PET scan, using at least 30% reduction in tumor metabolism as a response (n = 59), we also found no significant difference in survival among those with or without response.

Conclusion Among patients with resectable NSCLC treated with neoadjuvant chemotherapy, we found no evidence that tumor response by PET scan after chemotherapy is prognostic of survival; however, response by CT scan was associated with better survival.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• Does Computed Tomography or Positron Emission Tomography Response After Neoadjuvant Chemotherapy for Resectable Non–Small-Cell Lung Cancer Predict Survival?
  Edward F. Patz, Jr
  JCO 2008 26: 4542-4543 [Full Text]

Related Correspondence

• Standardization of Scanning for [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography
  Gerard G. Hanna, Jonathan McAleese, Tom B. Lynch, and Joe M. O'Sullivan
  JCO 2009 27: 831-832 [Full Text]

This article has been cited by other articles:

				R. J. Hicks Role of 18F-FDG PET in Assessment of Response in Non-Small Cell Lung Cancer J. Nucl. Med., May 1, 2009; 50(Suppl_1): 31S - 42S. [Abstract] [Full Text] [PDF]

				G. G. Hanna, J. McAleese, T. B. Lynch, and J. M. O'Sullivan Standardization of Scanning for [18F]Fluorodeoxyglucose Positron Emission Tomography J. Clin. Oncol., February 10, 2009; 27(5): 831 - 832. [Full Text] [PDF]

				T. Tanvetyanon, E. A. Eikman, and G. Bepler In Reply J. Clin. Oncol., February 10, 2009; 27(5): 832 - 832. [Full Text] [PDF]

				W. A. Weber The Use of Positron Emission Tomography versus Computerized Tomography Scans in the Assessment of Response to Therapy ASCO Educational Book, January 1, 2009; 2009(1): 474 - 478. [Abstract] [Full Text] [PDF]

				E. F. Patz Jr Does Computed Tomography or Positron Emission Tomography Response After Neoadjuvant Chemotherapy for Resectable Non-Small-Cell Lung Cancer Predict Survival? J. Clin. Oncol., October 1, 2008; 26(28): 4542 - 4543. [Full Text] [PDF]